- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01652898
A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers
A Single Centre Prospective, Randomized, Double Blind, Crossover, Three-treatment Periods PK, PD, Safety and Tolerability Study to Compare Bolus Administration of AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers After a Pilot Phase of AOP LDLA202 Safety and Local Tolerability Assessment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A single centre prospective, randomized, double blind study consisting of a local safety Pilot Phase and a triple-cross-over Main Study Phase.
In the pilot phase, 3 subjects will be administered a bolus with AOP LDLA202 vs. placebo (0.9% saline) simultaneously (same vein on the other body side). Following treatment of the first subject per cohort and assuming no safety concerns arise, second and third subjects will be treated in safety intervals of at least 3 hours between doses in individual subjects. On Day 3 after dosing a safety follow-up assessment will be done and all adverse events will be reported to the sponsor's medical monitor. Assuming no safety concerns arise, the sponsor's medical monitor will give green light for conduct of the Main Treatment Phase in writing.
In the main phase, 12 subjects will be treated with AOP LDLA202, ONO LDL50 and esmolol. Three doses per subject and day (=treatment period), all administered via big superficial veins, are planned with at least 1 hour observation period after each bolus injection. Each subject, if confirmed eligible, will complete three treatment periods in total in the main phase of the study.
ECG, blood pressure, local tolerability and adverse events will be monitored.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Pilsen, Czech Republic, 323 00
- Cepha s.r.o
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female human subjects, age 18-45 years, Caucasians
- Body weight of at least 50 kg, maximum of 90 kg. Body-mass index 18.5 to 30.0 kg/m2.
- Subjects without clinically relevant abnormalities as determined by baseline medical history, physical examination, blood pressure, heart rate and ear temperature at screening.
- Subjects without clinically relevant abnormalities as determined by blood count, coagulation tests, biochemistry, infectious disease screening, urinalysis, ECG, and 2D Echo at screening.
- Subject is willing and able to undergo procedures required by this protocol and gave written informed consent.
- Agreeing to not using any prescription and over the counter medications
- No history or presence of alcoholism or drug abuse
Exclusion Criteria:
- Subjects with history or presence of clinically relevant cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological, psychiatric or skin diseases.
- Subjects with bradycardia (heart rate below 50 bpm), tachycardia (heart rate above 100 bpm), hypotension (systolic blood pressure below 100 mmHg, and/or diastolic blood pressure below 70 mm Hg) at screening, history of clinically relevant arrhythmias.
- Subjects with clinically relevant cardiac supraventricular or ventricular arrhythmias.
- Subjects with atrioventricular block of grade II and III, sick sinus syndrome, sinoatrial block or congestive heart failure.
- Participation in a clinical drug study or bioequivalence study 60 days prior to present study.
- History of malignancy or other serious diseases.
- Any contraindication to blood sampling.
- History of i.v. drug abuse.
- Subjects with positive HIV tests, HBsAg or Hepatitis C tests or other acute, subacute or chronic infectious disease.
- Known history of hypersensitivity to any IMP.
- Refusal to abstain from smoking or consumption of tobacco products 48 hours before drug administration and during the study period.
- Refusal to abstain from alcohol, caffeine, or other xanthines, or grapefruit containing food or drinks for 72 hours before drug administration and during the study period.
- Refusal to abstain from strenuous activities for 7 days before screening and end-of-study examinations, before and during each study period.
- Subjects with anomalies of the venous and arterial vessels of the forearms or systemic vascular diseases.
- Pregnancy and/or breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Esmolol hydrochloride
Esmolol hydrochloride administered as intravenous bolus injection at low (0,5mg/kg), medium (1mg/kg) and high dose (1,5mg/kg) in 15/30/45 seconds once per subject
|
Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
|
Active Comparator: ONO LDL50
ONO LDL50 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
|
Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
|
Experimental: AOP LDLA202
AOP LDLA202 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
|
Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PK as measured by Cmax, Tmax, AUC, residual area, T1/2, CL and V
Time Frame: 7 hours
|
7 hours
|
Local tolerability as measured by signs and symptoms of inflammation judged by the clinical investigator on a 6-symptom, 4-point venous score.
Time Frame: 7 hours
|
7 hours
|
Safety as measured by Adverse events, clinical chemistry, hematology, urinalysis, physical examination, ECG (HR, PQ (PR), QRS, QT and QTc) and BP in mmHg.
Time Frame: 7 hours
|
7 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PD as measured by BP in mmHg and ECG parameters (HR, PQ, QRS, QT and QTc)
Time Frame: 7 hours
|
7 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ivan Ulc, Dr. med., Cepha s.r.o
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AOP LDLA202.101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Esmolol hydrochloride
-
Consorcio Centro de Investigación Biomédica en...Instituto de Salud Carlos IIIRecruitingDiabetes Mellitus | Cirrhosis | Oncologic DisordersSpain
-
Aretaieion University HospitalRecruitingPain, Postoperative | Analgesia | Pain, Acute | Nociceptive Pain | Inguinal Hernia Repair | Pain, Chronic Post-Surgical | EsmololGreece
-
AOP Orphan Pharmaceuticals AGCompletedHealthy Volunteers | Pharmacokinetics/Dynamics StudyCzech Republic
-
Novalead Pharma Private LimitedCompletedDiabetic Foot UlcerIndia
-
David N. Proctor, PhDCompleted
-
Xiumei SongNot yet recruitingAirway Obstruction | Stress Reaction | Catecholamine; Overproduction | Esmolol
-
Ciusss de L'Est de l'Île de MontréalNot yet recruitingAnesthesia | Opioid Use, Unspecified | Nociceptive PainCanada
-
Novalead Pharma Private LimitedUnknownDiabetic Foot UlcerMalaysia, United States, India
-
Zhiming JiangRecruitingAcute Respiratory Distress SyndromeChina
-
Beni-Suef UniversityUnknown